REGULATORY
PMDA Investigating Safety Risks of Eliquis, Other Anticoagulants for Acute Kidney Injury
The Pharmaceuticals and Medical Devices Agency (PMDA) is looking into new side effect risks for five anticoagulants, three biologic psoriasis therapies, and more drugs, flagging the possibility of label revisions in the near future. According to a risk communication update…
To read the full story
Related Article
- Label Revisions Ordered for 5 Anticoagulants Agents
November 22, 2023
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





